Diclazepam

Diclazepam

Diclazepam
Systematic (IUPAC) name
7-Chloro-5-(2-chlorophenyl)-1-methyl-1,3-dihydro-2H-1,4-benzodiazepin-2-one
Clinical data
Legal status
  • UK: Unscheduled
  • US: Not FDA approved
Routes of
administration
Oral, likely sublingual
Pharmacokinetic data
Bioavailability ?
Metabolism Hepatic
Biological half-life ~42h[1]
Excretion Renal
Identifiers
CAS Registry Number  YesY
PubChem CID:
ChemSpider
Chemical data
Formula C16H12Cl2N2O
Molecular mass 319.185 g/mol
 N   

Diclazepam (Ro5-3448), also known as chlorodiazepam and 2'-chloro-diazepam, is a benzodiazepine designer drug and functional analog of diazepam. It was first synthesized by Leo Sternbach and his team at Hoffman-La Roche in 1960.[2] It is not currently approved for use as a medication, but rather sold as a recreational drug and research chemical. Efficacy and safety have not been tested in humans.

In animal models, its effects are similar to diazepam, possessing anxiolytic, anticonvulsant, hypnotic, sedative, skeletal muscle relaxant, and amnestic properties.

Metabolism

Metabolism of this compound has been assessed,[1] revealing diclazepam has an approximate elimination half-life of 42 hours and undergoes N-demethylation to delorazepam, which can be detected in urine for 6 days following administration of the parent compound.[3] Other metabolites detected were lorazepam and lormetazepam which were detectable in urine for 19 and 11 days, respectively, indicating hydroxylation by cytochrome P450 enzymes occurring concurrently with N-demethylation.

See also

References

  1. ^ a b
  2. ^ US 3136815, "Amino substituted benzophenone oximes and derivatives thereof" 
  3. ^